SK Bioscience Reports 2025 Operating Loss of KRW 119.1B, SK Chemical Maintains 66.35% Stake – Routine Conglomerate Disclosure
SK Bioscience, an SK Group affiliate, reported total assets of KRW 2.18 trillion, liabilities of KRW 459.6B, and equity of KRW 1.73 trillion as of end-2025.
Revenue of KRW 185.7B, operating loss of KRW 119.1B, and net loss of KRW 57.9B, continuing losses.
Largest shareholder is SK Chemical (66.35%); no treasury shares; minimal executive ownership.
Subsidiaries include SK bioscience USA, SK bioscience Germany, and IDT Biologika (60.65%).
Board consists of 8 members (2 inside, 1 non-executive, 5 outside); committees including audit committee are operating.
Related party transactions: office leases from SK Gas and SK Chemical (KRW 15.9B), land and building sale to SK Gas (KRW 50.6B).
Transaction with related foundation: service revenue of KRW 146M from Haengbok F&C.
[AI Comprehensive Analysis]This is a routine conglomerate status disclosure with no direct impact on stock price such as capital raising or shareholder return policies. The loss trend and high affiliate dependency are risk factors, but near-term stock impact is likely limited.
KOSPI Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]